NASDAQ:VYNE - VYNE Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $21.00
Forecasted Upside: 677.78 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
0 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$2.70 As of 07/23/2021 01:00 AM ET

▼ -0.09 (-3.23%)

1 month | 3 months | 12 months

Get New VYNE Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for VYNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYNE

^$21.00

▲ +677.78% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for VYNE Therapeutics in the last 3 months. The average price target is $21.00, with a high forecast of $28.00 and a low forecast of $11.00. The average price target represents a 677.78% upside from the last price of $2.70.

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in VYNE Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/31/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/30/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/29/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/27/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/25/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/25/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/24/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/7/2021	HC Wainwright	Lower Price Target	Buy	$14.00 ➝ $11.00	High
12/17/2020	Maxim Group	Reiterated Rating	Positive		High
10/5/2020	HC Wainwright	Boost Price Target	Buy	$12.00 ➝ $14.00	High
10/2/2020	Lifesci Capital	Reiterated Rating	Outperform		High
10/2/2020	Northland Securities	Reiterated Rating	Buy	$24.00	Low
8/7/2020	HC Wainwright	Lower Price Target	Buy	$14.00 ➝ $12.00	Low
8/6/2020	Ci Capital	Reiterated Rating	Buy	$28.00	Low
8/4/2020	Northland Securities	Reiterated Rating	Buy		High
6/1/2020	Northland Securities	Boost Price Target	Outperform	$14.00 ➝ $24.00	Low
6/1/2020	HC Wainwright	Boost Price Target	Buy	$10.00 ➝ $14.00	Low
5/21/2020	Northland Securities	Initiated Coverage	Outperform	$14.00	High
5/13/2020	Barclays	Boost Price Target	Overweight	$8.00 ➝ $12.00	High
5/12/2020	HC Wainwright	Boost Price Target	Buy	$8.00 ➝ $10.00	High
4/7/2020	Barclays	Lower Price Target	Overweight	$32.00 ➝ $8.00	High
4/7/2020	HC Wainwright	Lower Price Target	Buy	$32.00 ➝ $8.00	High
3/25/2020	Barclays	Initiated Coverage	Overweight	$32.00	Medium
3/11/2020	Bank of America	Initiated Coverage	Buy	$32.00	High
2/27/2020	HC Wainwright	Lower Price Target	Buy	$40.00 ➝ $36.00	High
10/18/2019	HC Wainwright	Initiated Coverage	Buy	$44.00	High
5/2/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$100.00	Medium
2/27/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$100.00	Low
11/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$100.00	Medium
10/9/2018	Jefferies Financial Group	Lower Price Target	Hold	$28.00	Low
10/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$100.00	High
9/6/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$100.00	Medium
7/24/2018	Roth Capital	Initiated Coverage	Buy	$116.00	High
7/24/2018	KeyCorp	Initiated Coverage	Buy		High
4/25/2018	Guggenheim	Reiterated Rating	Buy	$44.00	High
4/9/2018	Jefferies Financial Group	Downgrade	Buy ➝ Hold		N/A
2/20/2018	JMP Securities	Initiated Coverage	Mkt Outperform ➝ Outperform	$176.00 ➝ $176.00	High
2/20/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$192.00	High
2/20/2018	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$164.00	High
2/19/2018	Guggenheim	Initiated Coverage	Buy ➝ Buy	$208.00	High

(Data available from 7/25/2016 forward)

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Today's Range

Now: $2.70

$2.67

$2.78

50 Day Range

MA: $3.50

$2.69

$4.11

52 Week Range

Now: $2.70

$2.62

$13.20

Volume

281,417 shs

Average Volume

845,592 shs

Market Capitalization

$138.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of VYNE Therapeutics?

The following Wall Street analysts have issued reports on VYNE Therapeutics in the last year: Ci Capital, HC Wainwright, Lifesci Capital, Maxim Group, Northland Securities, and Zacks Investment Research.
View the latest analyst ratings for VYNE.

What is the current price target for VYNE Therapeutics?

3 Wall Street analysts have set twelve-month price targets for VYNE Therapeutics in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 677.8%. Ci Capital has the highest price target set, predicting VYNE will reach $28.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for VYNE Therapeutics in the next year.
View the latest price targets for VYNE.

What is the current consensus analyst rating for VYNE Therapeutics?

VYNE Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VYNE will outperform the market and that investors should add to their positions of VYNE Therapeutics.
View the latest ratings for VYNE.

What other companies compete with VYNE Therapeutics?

Other companies that are similar to VYNE Therapeutics include Veru, VistaGen Therapeutics, AC Immune, Greenwich LifeSciences, Inventiva, Spectrum Pharmaceuticals, Aldeyra Therapeutics, KalVista Pharmaceuticals, Clovis Oncology, Atossa Therapeutics, Werewolf Therapeutics, Vaccitech, Evelo Biosciences, Applied Therapeutics and Basilea Pharmaceutica.

How do I contact VYNE Therapeutics' investor relations team?

VYNE Therapeutics' physical mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The company's listed phone number is 800-775-7936 and its investor relations email address is [email protected] The official website for VYNE Therapeutics is www.menlotherapeutics.com.